Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
2.030
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Recap: C4 Therapeutics Q1 Earnings
↗
May 04, 2023
Via
Benzinga
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Where C4 Therapeutics Stands With Analysts
↗
March 28, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
↗
February 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
↗
February 24, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics's Return On Capital Employed Overview
↗
November 23, 2022
Via
Benzinga
C4 Therapeutics: Q3 Earnings Insights
↗
November 03, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
↗
February 03, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
January 25, 2023
Via
Benzinga
Recap: C4 Therapeutics Q2 Earnings
↗
August 04, 2022
C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
↗
November 25, 2022
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
↗
November 25, 2022
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.
Via
Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
↗
November 25, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
Via
Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
↗
November 25, 2022
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
November 24, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
↗
November 04, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 03, 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
↗
October 11, 2022
Upgrades
Via
Benzinga
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
September 29, 2022
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics's Return On Capital Employed Insights
↗
August 22, 2022
According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million.
Via
Benzinga
C4 Therapeutics's Return On Capital Employed Overview
↗
May 27, 2022
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million.
Via
Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
↗
September 19, 2022
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
